|| Poor Clinical Research Data ||
A directive by the National ask Force to the ICMR to study the clinical features of patients in the Indian context and their diagnostic and prognostic value in different age and gender groups has remained on paper for the last three months.
As a result, there is no centralised information yet on key questions such as profile of those falling sick, how are comorbidities influencing outcomes, and what is the actual cause of death. Even though India has nearly 8 lakh cases, there is no information on whether outcomes are different for patients receiving hydroxychloroquine, remdesivir or plasma therapy.
The lack of these crucial bits of information is hampering clinical decisions of doctors and public policy regarding the outbreak management, experts said. Task force members said the issue was discussed several times in March-April after which the ICMR was asked to develop a protocol for generating the dataset. But, they said, the project never took off.
The idea was to generate data on a standard format from every hospital where patients are getting treated and analyse them nationally to inform policy decisions, said a task force member. It was an important exercise that would have greatly helped our understanding of the disease but it did not get implemented. ICMR director general Dr Balram Bhargava could not be contacted for his comments despite several attempts.
About SocialNewsXYZ
An Indo-American News website. It covers Gossips, Politics, Movies, Technolgy, and Sports News and Photo Galleries and Live Coverage of Events via Youtube.
The website is established in 2015 and is owned by AGK FIRE INC.
Related
Summary
Title
Prof K Nageshwar: Poor Clinical Research Data (Video)
Description
|| Poor Clinical Research Data ||
A directive by the National ask Force to the ICMR to study the clinical features of patients in the Indian context and their diagnostic and prognostic value in different age and gender groups has remained on paper for the last three months.
As a result, there is no centralised information yet on key questions such as profile of those falling sick, how are comorbidities influencing outcomes, and what is the actual cause of death. Even though India has nearly 8 lakh cases, there is no information on whether outcomes are different for patients receiving hydroxychloroquine, remdesivir or plasma therapy.
The lack of these crucial bits of information is hampering clinical decisions of doctors and public policy regarding the outbreak management, experts said. Task force members said the issue was discussed several times in March-April after which the ICMR was asked to develop a protocol for generating the dataset. But, they said, the project never took off.
The idea was to generate data on a standard format from every hospital where patients are getting treated and analyse them nationally to inform policy decisions, said a task force member. It was an important exercise that would have greatly helped our understanding of the disease but it did not get implemented. ICMR director general Dr Balram Bhargava could not be contacted for his comments despite several attempts.
